1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Tanzania Pharmaceuticals and Healthcare Report Q4 2016

Tanzania Pharmaceuticals and Healthcare Report Q4 2016

  • October 2016
  • -
  • Business Monitor International
  • -
  • 59 pages

Includes 3 FREE quarterly updates

BMI View:

Tanzania's pharmaceutical market will continue to suffer from a lack of domestic production as the majority of the country's medicine needs remain sourced from abroad. Despite government efforts to boost local pharmaceutical production, generic drugmakers, largely from India will dominate Tanzania's pharmaceutical landscape. Moreover, supply chain issues will deter direct investment prospects by multinational drugmakers. Opportunities in the Tanzanian healthcare market will become visible over the long-term, however, supported by the gradual introduction of compulsory health insurance for households and the government's its commitment to expanding healthcare coverage in underserved areas.


Headline Expenditure Projections

- Pharmaceuticals: TZS900bn (USD442mn) in 2015 to an expected TZS1.01trn (USD463mn) in 2016; +12.7% growth in local currency terms and +4.8% in US dollar terms. Forecast maintained from Q316.

- Healthcare: TZS4.96trn (USD2.44bn) in 2015 to TZ5.56trn (USD2.54bn) in 2016; +11.8% growth in local currency terms, and +4.0% in US dollar terms. Forecast maintained from Q316. In our Q416 Pharmaceutical Risk/Reward Index (RRI) Tanzania's score of 33.3 out of 100 marks a slight worsening from its score last quarter of 34.5, and lowers its position by one rank to 23rd place out of 31 countries analysed in the whole Middle East and Africa (MEA) region. A sizeable counterfeiting industry, poor healthcare funding, corruption, regulatory environment deficiencies and a number of other issues will conspire to keep Tanzania in a similarly lowly position in the MEA matrix. In particular, issues relating to patent approvals and the regulatory system remain a major issue for foreign research-based pharmaceutical players. Nevertheless, in comparison with many other African markets, Tanzania offers more commercial promise and a more stable overall business environment.

Table Of Contents

Tanzania Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Tanzania 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Tanzania 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Tanzania 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Tanzania 2012-2020) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Tanzania 2012-2020) 18
Tanzania - Pharmaceutical Trade - Tanzania - Q4 2016 19
Table: Pharmaceutical Trade Data And Forecasts (Tanzania 2014-2020) 21
Table: Pharmaceutical Trade Data And Forecasts Local Currency (Tanzania 2014-2020) 21
Industry Risk/Reward Index 22
Middle East And Africa Risk/Reward Index - Q4 2016 22
Tanzania Risk/Reward Index 30
Rewards 30
Risks 31
Regulatory Review 32
Intellectual Property Issues 33
Pricing Regime 33
Market Overview 35
Healthcare Sector 35
Research and Development 39
Clinical Trials 39
Epidemiology 41
Competitive Landscape 45
Research-Based Industry 45
Table: Multinational Market Activity 46
Generic Drugmakers 47
Pharmaceutical Retail Sector 47
Demographic Forecast 48
Table: Population Headline Indicators (Tanzania 1990-2025) 49
Table: Key Population Ratios (Tanzania 1990-2025) 49
Table: Urban/Rural Population and Life Expectancy (Tanzania 1990-2025) 50
Table: Population By Age Group (Tanzania 1990-2025) 50
Table: Population By Age Group % (Tanzania 1990-2025) 51
Tanzania Pharmaceuticals and Healthcare Report Q4 2016$$
Glossary 53
Methodology 55
Pharmaceutical Expenditure Forecast Model 55
Healthcare Expenditure Forecast Model 55
Notes On Methodology 56
Risk/Reward Index Methodology 57
Index Overview 58
Table: Pharmaceutical Risk/Reward Index Indicators 58
Indicator Weightings 59

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.